Delcath Systems Inc DCTH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 03/05/21 EST
17.91quote price arrow up+0.64 (+3.71%)
Volume
122,831
52 week range
5.15 - 25.18

...

Loading . . .

KEY STATS

  • Open17.69
  • Day High17.91
  • Day Low16.01
  • Prev Close17.27
  • 52 Week High25.18
  • 52 Week High Date02/11/21
  • 52 Week Low5.15
  • 52 Week Low Date03/18/20
  • Market Cap111.94M
  • Shares Out6.25M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.67
  • 1 Year % Change62.82

RATIOS/PROFITABILITY

  • EPS (TTM)252.89
  • P/E (TTM)0.07
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-18.692M
  • ROE (MRQ)-2,606.75%
  • Revenue (MRQ)1.66M
  • Gross Margin (MRQ)56.94%
  • Net Margin (MRQ)-279.89%
  • Debt To Equity (MRQ)61.05%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Delcath Systems Inc News

There is no recent news for this security.

Latest DCTH News From Our Partners

QUOTE FINDER

Profile

MORE
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT...
Roger Stoll Ph.D.
Non-Executive Chairman
Gerard Michel
Chief Executive Officer
John Purpura
Chief Operating Officer
Christine Padula CPA
Chief Accounting Officer
Address
1633 Broadway Ste 22C
New York, NY
10019-6708
United States